• Zepbound, Mounjaro shortages drag on

    Four more solutions of Zepbound and Mounjaro are in limited supply, and the shortages have prolonged, the FDA said April 17. 
  • Weight loss drugs will widen health disparities, experts say

    While weight loss drugs have been touted as a game-changer for the nation's obesity epidemic, many Americans who would benefit most from the medications often lack access, experts told the Los Angeles Times in an April 15 report.
  • Researchers explore 9 more diseases GLP-1s could treat

    Researchers are expanding horizons for the diseases and disorders that GLP-1s such as Ozempic, Mounjaro and Wegovy could treat.
  • Experts call for more data on weight loss meds as fertility drugs

    Physicians and researchers say more data is needed on pregnancy outcomes in patients taking GLP-1s as a growing number of women turn to the class of weight loss medications in hopes of reducing their risk of pregnancy complications or increasing their chance of conceiving, Bloomberg reported April 18. 
  • Eli Lilly to seek label expansion for Mounjaro, Zepbound

    After achieving promising outcomes for patients with sleep apnea, Eli Lilly said April 17 it plans to seek a wider FDA approval for Mounjaro and Zepbound. 
  • More evidence refutes link between weight loss drugs, suicidal thoughts

    Available evidence does not suggest a link between the use of GLP-1 receptor agonists, including Ozempic and Wegovy, and suicidal thoughts or actions, according to a review from drug regulators in Europe. 
  • A possible Ozempic baby boom

    Surprise pregnancies may be an unexpected side effect experienced by women who use Ozempic or other GLP-1 medications, The Washington Post reported April 5.
  • Ozempic predecessor may slow Parkinson's progression, new study shows

    A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson's disease, according to findings published April 3 in The New England Journal of Medicine. 
  • FDA confirms Zepbound shortage

    After patients and clinicians reported weeklong back orders of Zepbound, Eli Lilly's new weight loss drug, the FDA confirmed shortages of two Zepbound solutions. 
  • Costco to offer weight loss program

    Six months after Costco announced its entrance into the healthcare industry with $29 virtual primary care visits, the big box retailer is launching a specialized weight loss program exclusively for its members. 
  • Up to 15% of patients on weight loss drugs may be 'non-responders'

    Physicians estimate up to 15% of people who try GLP-1s — the popular class of anti-obesity medications that includes drugs that include Ozempic and Wegovy — lose less than 5% of their body weight, The Wall Street Journal reported April 1. 
  • Weight loss drugs could prevent sleep apnea, shrink CPAP market

    By 2030, between 2.5 million and 3.8 million cases of obstructive sleep apnea can be avoided — a 10.7% reduction in overall prevalence — based on estimates of patients taking Wegoy. 
  • $5 Ozempic? New study sparks calls for Novo Nordisk to cut prices

    While the list price for a monthly supply of Ozempic in the U.S. nears $1,000, new research indicates it could be manufactured for less than $5 per month, sparking calls from lawmakers for Novo Nordisk to lower the price of its blockbuster diabetes and weight loss drug. 
  • Cedars-Sinai confirms surgery risks for patients taking weight loss drugs

    Among nearly 1 million patients who underwent upper or lower endoscopy procedures, those prescribed GLP-1s, such as Ozempic or Wegovy, were 33% more likely to experience aspiration pneumonia than other patients. 
  • Wegovy sidesteps the 'forever drug' problem

    Nonadherance seems to be a nonissue for patients taking new weight loss drugs, The New York Times reported March 24. 
  • 5 updates on weight loss drugs

    Sen. Bernie Sanders wants to schedule a meeting with Novo Nordisk's CEO after researchers said its blockbuster Type 2 diabetes drug, Ozempic, could remain profitable if it was made for less than $5, Bloomberg reported March 28. 
  • Weight loss drugs alter bariatrics

    Some bariatric surgeons are noticing a decrease in referrals because of the increasing popularity of GLP-1s, which mimic a gut hormone that suppresses appetite and makes patients feel full. 
  • Medicare paves way for weight loss drug coverage: WSJ

    Less than two weeks after Novo Nordisk's weight loss drug Wegovy was approved to reduce the risk of heart attacks and strokes, CMS has issued guidance for Medicare coverage of weight loss drugs, The Wall Street Journal reported March 21. 
  • Patients turn to weight loss meds to prevent pregnancy complications

    Physicians are seeing more women turn to weight loss medications before they become pregnant in hopes of lowering their risks of having a miscarriage and other complications, such as preeclampsia and preterm birth. 
  • The '3rd generation' of weight loss drugs

    Anita Courcoulas, MD, defines GLP-1s as "generation one;" dual GLP-1 and GIPs as the second; and a triple threat of GLP-1, GIP and GCGRs as the third generation of weight loss drugs. 

Featured Whitepapers

Featured Webinars

>